Thioredoxin reductase as a pathophysiological factor and drug target

European Journal of Biochemistry

Volumn 267, Issue 20, 2000, Pages 6118-6125

  Becker, Katja ^a   Gromer, Stephan ^b   Heiner Schirmer, R ^b   Müller, Sylke ^c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

Author keywords

Antioxidant systems; Aurothioglucose; Carmustine; Diselenide; Drug resistance; Epstein Barr virus; Leprosy; Malaria; Rheumatoid arthritis; Selenium metabolism

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ANTHRACYCLINE DERIVATIVE; AURANOFIN; AUROTHIOGLUCOSE; AZELAIC ACID; CARMUSTINE; CISPLATIN; ENZYME INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 2; ISOTRETINOIN; NITROSOUREA DERIVATIVE; SELENIUM; SELENIUM DERIVATIVE; THIOREDOXIN; THIOREDOXIN REDUCTASE;

ANTIOXIDANT ACTIVITY; CHRONIC DISEASE; DIABETIC NEPHROPATHY; DRUG RESISTANCE; DRUG TARGETING; ENZYME ANALYSIS; ENZYME SPECIFICITY; HEART ARRHYTHMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; LEPROSY; MALARIA; NONHUMAN; NUTRITIONAL DEFICIENCY; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; REDUCTION; RHEUMATOID ARTHRITIS; SHORT SURVEY; SJOEGREN SYNDROME; TUMOR;

CHRONIC DISEASE; DIMERIZATION; HUMANS; NEOPLASMS; PROTEIN SUBUNITS; SELENIUM; THIOREDOXIN; THIOREDOXIN REDUCTASE (NADPH);

EID: 0033775650     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1327.2000.01703.x     Document Type: Short Survey

References (59)

1. AhpF and other NADH: Peroxiredoxin oxireductases, homologues of low Mr thioredoxin reductase
2. Thioredoxin reductase. Two modes of catalysis have evolved
3. Physiological functions of thioredoxin and thioredoxin reductase
4. Thioredoxin reductase
5. News and views on thioredoxin reductase
6. The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia coli
7. The role of the C-terminus for catalysis of the large thioredoxin reductase from Plasmodium falciparum
8. A new selenoprotein from human lung adenocarcinoma cells: Purification, properties, and thioredoxin reductase activity
9. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene
10. Molecular cloning and characterization of a mitochondrial selenocysteine-containing thioredoxin reductase from rat liver
11. Selenocysteine
12. Selenium metabolism, selenoproteins and mechanisms of cancer prevention: Complexities with thioredoxin reductase
13. Deoxyribonucleoside triphosphate pools and growth of glutathione-depleted 3T6 mouse fibroblasts
14. NK-lysin, a disulfide-containing effector peptide of T-lymphocytes, is reduced and inactivated by human thioredoxin reductase. Implication for a protective mechanism against NK-lysin cytotoxicity
15. Efficient reduction of lipoamide and lipoic acid by mammalian thioredoxin reductase
16. Reduction of dehydroascorbate to ascorbate by the selenoenzyme thioredoxin reductase
17. Reduction of the ascorbyl free radical to ascorbate by thioredoxin reductase
18. S-Nitrosoglutathione is cleaved by the thioredoxin system with liberation of glutathione and redox regulating nitric oxide
19. Enzyme inactivation through sulfhydryl oxidation by physiologic NO-carriers
20. The thioredoxin and glutaredoxin systems are efficient electron donors to human plasma glutathione peroxidase
21. Elevation of plasma thioredoxin levels in HIV-infected individuals
22. Measurements of plasma glutaredoxin and thioredoxin in healthy volunteers and during open-heart surgery
23. Rat and calf thioredoxin reductase are homologous to glutathione reductase with a carboxyl-terminal elongation containing a conserved catalytically active penultimate selenocysteine residue
24. Selenium inhibition of DNA synthesis in mouse mammary epithelial cell line YN-4
25. Cloning and sequencing of a human thioredoxin reductase
26. Possible roles of an adult T-cell leukemia (ATL)-derived factor/thioredoxin in the drug resistance of ATL to adriamycin
27. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): Thioredoxin mRNA is elevated in some human tumors
28. The thioredoxin/thioredoxin reductase redox system and control of cell growth
29. High rates of thioredoxin secretion correlate with growth arrest in hepatoma cells
30. Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2
31. Redox regulation of cell signaling by selenocysteine in mammalian thioredoxin reductases
32. Redox regulation of transcriptional activators
33. A mutation in a thioredoxin reductase homolog suppresses p53-induced growth inhibition in the fission yeast Schizosaccharomyces pombe
34. EF-hands calcium binding regulates the thioredoxin reductase/thioredoxin electron transfer in human keratinocytes
35. Autoantibody to thioredoxin reductase in an ovarian cancer patient
36. Protective activity of adult T cell leukemia-derived factor (ADF) against tumor necrosis factor-dependent cytotoxicity on U937 cells
37. The 58 kDa mouse selenoprotein is a BCNU-sensitive thioredoxin reductase
38. The mechanism of action of the nitrosourea anti-tumor drugs on thioredoxin reductase, glutathione reductase and ribonucleotide reductase
39. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II)
40. Disulfide reductases are destabilized by physiologic concentrations of NADPH
41. Increased expression of human thioredoxin/adult T cell leukemia-derived factor in Sjogren's syndrome
42. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds
43. Aurothioglucose inhibits murine thioredoxin reductase activity in vivo
44. Expression of the thioredoxin-thioredoxin reductase system in the inflamed joints of patients with rheumatoid arthritis
45. Levels of major selenoproteins in T cells decrease during HIV infection and low molecular mass selenium compounds increase
46. Opposing regulatory effects of thioredoxin and eosinophil cytotoxicity-enhancing factor on the development of human immunodeficiency virus 1
47. Recombinant putative glutathione reductase of Plasmodium falciparum exhibits thioredoxin reductase activity
48. Thioredoxin reductase from Plasmodium falciparum: Evidence for interaction between the C-terminal cysteine residues and the active site disulfide-dithiol
49. Characterization of two E. histolytica proteins that inactivate reactive oxygen species
50. Recombinant expression and biochemical characterization of an NADPH: Flavin oxidoreductase from Entamoeba histolytica
51. Metronidazole resistance in the protozoan parasite Entamoeba histolytica is associated with increased expression of iron-containing superoxide dismutase and peroxiredoxin and decreased expression of ferredoxin 1 and ravin reductase
52. Thioredoxin reductase-thioredoxin fusion enzyme from Mycobacterium leprae: Comparison with the separately expressed thioredoxin reductase
53. Purification and functional analysis of the Mycobacterium leprae thioredoxin/thioredoxin reductase hybrid protein
54. AhpC, oxidative stress and drug resistance in Mycobacterium tuberculosis
55. High-level expression in Escherichia coli of selenocysteine-containing rat thioredoxin reductase utilizing gene fusions with engineered bacterial-type SECIS elements and co-expression with the selA, selB and SelC genes
56. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide
57. Differential expression of selenoproteins by human skin cells and protection by selenium from UVB-radiation-induced cell death
58. Protection against reperfusion-induced arrhythmias by human thioredoxin
59. Thioredoxin reductase mediates cell death effects of the combination of beta interferon and retinoic acid